CGM Longevity Target Ranges for Women: What Your Continuous Glucose Monitor Numbers Actually Mean

Why CGM Data Means Something Different for Women

A CGM is not just a diabetes tool. In the context of longevity medicine, it is a real-time readout of metabolic resilience, one that behaves differently in female physiology at every life stage. Female sex hormones, body composition, and reproductive status all shape glucose kinetics in ways that most CGM reference guides, written with diabetic male trial populations in mind, simply do not address.

Women have higher adipose-to-lean-mass ratios than men at equivalent BMIs, which affects insulin sensitivity. Estrogen itself is an insulin sensitizer; the loss of estrogen at menopause reliably worsens fasting glucose and postprandial spikes even in previously metabolically healthy women. The menstrual cycle introduces a monthly oscillation in insulin sensitivity that makes CGM patterns read completely differently in the luteal phase versus the follicular phase.

None of this is exotic biology. It is routine female physiology, and your CGM data needs to be interpreted through that lens.

The Evidence Gap You Should Know About

Landmark CGM studies, including the Dexcom DIAMOND trial and the foundational continuous glucose monitoring work cited by the 2024 ADA Standards of Care, enrolled populations that were majority male or did not stratify results by sex. The iCGM accuracy standards published by the FDA likewise do not require sex-disaggregated performance data. Longevity-medicine CGM targets for non-diabetic women are therefore largely extrapolated from diabetes trial data, epidemiologic cohorts, and a smaller body of observational work in healthy adults. Where data is directly from female-only or female-majority cohorts, this article says so explicitly.

Core CGM Metrics and What Each One Measures

Understanding your CGM printout starts with knowing which numbers to look at, because a single fasting glucose misses most of the story.

Mean Glucose

Your average glucose over a 14-day sensor wear is the anchor metric. In large epidemiologic cohorts tracking cardiovascular mortality, mean glucose values consistently above 100 mg/dL in non-diabetic individuals correlate with increased risk even before diabetes criteria are met. The ARIC cohort data, which did include substantial female representation, showed that women with mean fasting glucose in the 100-109 mg/dL range had measurably elevated cardiovascular risk compared with women below 90 mg/dL. Longevity-focused clinicians generally target a mean CGM glucose of 79-100 mg/dL for non-diabetic women.

Time in Range (TIR)

TIR is the percentage of sensor readings within a defined glucose band. The ADA and international consensus guidelines set 70-180 mg/dL as the standard band for type 1 and type 2 diabetes, with a target of more than 70% of the day. Longevity medicine narrows that band to 70-140 mg/dL and aims for more than 90% TIR, because the goal is not diabetes management but metabolic optimization.

Glucose Variability (CV and SD)

Coefficient of variation below 36% is the threshold associated with lower hypoglycemia risk in diabetic populations per the Kovatchev consensus paper, and longevity clinicians apply this same ceiling to non-diabetic CGM users. High variability, even when mean glucose looks acceptable, predicts endothelial stress and is independently associated with cognitive decline risk in older adults.

Time Below Range (TBR)

Readings below 70 mg/dL should represent less than 4% of the day, and readings below 54 mg/dL less than 1%, per the international CGM consensus. Women on low-calorie diets, women who exercise intensively, and women in the late luteal phase are at higher risk of asymptomatic dips into this zone.

How Hormones Change Your CGM Readings Across the Menstrual Cycle

The menstrual cycle creates a predictable two-phase pattern in CGM data that most commercial CGM apps and reports do not label or account for. Understanding this framework lets you interpret spikes and dips without unnecessary alarm.

Follicular Phase (Days 1-14): Higher Insulin Sensitivity

During the follicular phase, rising estrogen improves peripheral insulin sensitivity. CGM readings in this phase tend to be lower and flatter. Post-meal glucose peaks are generally smaller, and return to baseline is faster. A 30-minute post-meal spike to 120 mg/dL followed by a return to 85 mg/dL within 90 minutes is a normal, healthy pattern in this phase.

Luteal Phase (Days 15-28): Progesterone-Driven Insulin Resistance

Progesterone is a partial insulin antagonist. Research published in Diabetes Care documented that insulin requirements in women with type 1 diabetes increase by approximately 10-20% in the luteal phase compared with the follicular phase. In non-diabetic women wearing CGMs, the same physiology shows up as modestly higher fasting glucose (often 5-10 mg/dL above follicular-phase baseline), larger post-meal spikes, and slower return to baseline. This is not a sign of metabolic disease. It is expected female physiology.

Practical point: if you are tracking your CGM data for longevity purposes, report averages and TIR separately for follicular and luteal phases, or at minimum flag which phase you were in during any anomalous readings.

Premenstrual Days

The 2-3 days before menstruation often show the highest glucose variability of the cycle. Some women also experience reactive hypoglycemia in this window as progesterone drops sharply. A dip to 65 mg/dL on day 27 of a regular cycle is a different clinical finding than the same dip on day 10.

PCOS: When Insulin Resistance Is the Primary Story

Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, affecting 8-13% of women globally. Insulin resistance is present in an estimated 50-70% of women with PCOS, regardless of weight status, making CGM one of the most informative monitoring tools in this population.

What CGM Typically Shows in PCOS

Women with PCOS and insulin resistance tend to show exaggerated postprandial spikes (frequently exceeding 140-160 mg/dL after moderate-carbohydrate meals), prolonged return to baseline (sometimes 3-4 hours rather than the typical 2 hours), and elevated fasting glucose even when HbA1c remains in the normal range. The Rotterdam Consensus on PCOS identifies metabolic risk as a central feature of the syndrome, and CGM data adds granularity that quarterly HbA1c simply cannot provide.

CGM as a Fertility-Planning Tool in PCOS

For women with PCOS who are trying to conceive, glucose variability directly affects ovulation regularity and implantation outcomes. ASRM practice guidelines note that insulin-sensitizing strategies improve ovulatory frequency. CGM data can help you and your clinician quantify whether dietary or pharmacologic interventions are actually improving your glucose profile before proceeding to fertility treatments.

Perimenopause and Menopause: The Metabolic Inflection Point

The years surrounding the final menstrual period are the single most consequential metabolic window for many women, and CGM data captures changes that standard labs often miss for years.

Estrogen Loss and Glucose Kinetics

Estrogen acts at multiple points in glucose metabolism: it promotes GLUT4 transporter expression in muscle, improves hepatic insulin sensitivity, and modulates pancreatic beta-cell function. As estradiol falls during perimenopause, all of these effects attenuate. A 2020 analysis in Menopause found that women with lower endogenous estradiol had significantly higher odds of developing type 2 diabetes, independent of age and BMI.

On the CGM, perimenopausal and postmenopausal women often notice:

• Fasting glucose creeping upward by 5-15 mg/dL compared with premenopausal readings
• More frequent post-meal spikes above 140 mg/dL from meals that were previously well-tolerated
• Greater glycemic variability during hot flash episodes (vasomotor symptoms are associated with catecholamine surges that can acutely raise glucose)
• Worsened overnight glucose regulation, particularly in women with sleep disruption from night sweats

Menopausal Hormone Therapy and CGM Readings

For women on menopausal hormone therapy (MHT), the route of estrogen delivery matters to CGM data. Transdermal estradiol does not undergo first-pass hepatic metabolism, which preserves its insulin-sensitizing effect more cleanly than oral estradiol. Women starting transdermal MHT often see a measurable improvement in post-meal CGM spikes and fasting glucose within 8-12 weeks. Oral progestogens (particularly medroxyprogesterone acetate) can partially offset this benefit through their anti-insulin effects; micronized progesterone is more metabolically neutral per The Menopause Society position statement.

This is an active area of research, not a settled clinical consensus. CGM can help you objectively track whether your MHT regimen is improving or worsening your glucose profile.

Pregnancy and Lactation: A Required Section

Pregnancy fundamentally changes CGM targets. This is not a drug article, but because CGM devices are frequently used during pregnancy and the glucose thresholds change substantially, the following guidance is required reading for any woman who is pregnant, trying to conceive, or recently postpartum.

Gestational Glucose Targets

Normal pregnancy is a state of physiologic insulin resistance, particularly in the second and third trimesters, driven by human placental lactogen, cortisol, and progesterone. Paradoxically, first-trimester glucose in non-diabetic pregnant women is often lower than preconception values. ACOG Practice Bulletin 190 and ADA Standards of Care Section 15 (Diabetes in Pregnancy) define CGM TIR targets for pregnant women with diabetes as 63-140 mg/dL for more than 70% of the day.

For non-diabetic pregnant women, no formal CGM longevity target exists in society guidelines. Observational data suggests that even in normal pregnancy, post-meal glucose rarely exceeds 120-130 mg/dL in metabolically healthy women, and mean glucose runs lower than in non-pregnant adults, averaging roughly 88-95 mg/dL in the first trimester.

Gestational Diabetes Monitoring

Women diagnosed with gestational diabetes mellitus (GDM) who use CGM should be guided by ACOG and ADA thresholds: fasting glucose below 95 mg/dL, one-hour post-meal below 140 mg/dL, two-hour post-meal below 120 mg/dL. The CONCEPTT trial (NEJM 2017) remains the most important randomized trial of CGM in pregnant women with type 1 diabetes, showing significant reductions in neonatal intensive care admissions and large-for-gestational-age births in the CGM group.

Postpartum and Lactation

Breastfeeding lowers maternal glucose significantly, a clinically meaningful effect for women with GDM or prediabetes. CDC and ACOG both recommend post-GDM glucose testing at 4-12 weeks postpartum and then every 1-3 years, since up to 50% of women with GDM develop type 2 diabetes within 10 years. CGM in the postpartum period can detect glucose patterns that a single oral glucose tolerance test at 6 weeks will miss.

CGM sensors themselves are external devices with no systemic pharmacologic activity, so lactation safety from a device standpoint is not a concern.

Trying to Conceive

Preconception glycemic optimization matters. Elevated periconceptional glucose and HbA1c are associated with increased rates of neural tube defects and spontaneous pregnancy loss, per ACOG guidance on preconception care. Women with PCOS or prediabetes planning pregnancy should use CGM data to confirm glucose is well-controlled before conception, not just in the normal range on standard labs.

Who Benefits Most from CGM in Longevity Medicine: Life-Stage Guide

Not every woman needs a CGM. Here is an honest breakdown by life stage and condition.

Reproductive Years (Ages 18-40)

Strong candidates: women with PCOS, women with a family history of type 2 diabetes, women on medications that affect insulin sensitivity (including certain antipsychotics, corticosteroids, or combined oral contraceptives in susceptible individuals). Standard metabolic labs can miss real-world glucose variability entirely in this group.

Moderate-benefit candidates: high-performance athletes who want to optimize carbohydrate timing, or women experiencing unexplained fatigue, reactive hypoglycemia symptoms, or irregular cycles where metabolic dysfunction is suspected.

Trying to Conceive and Pregnancy

High benefit in PCOS-related anovulation, pregestational diabetes, and any prior GDM diagnosis. Benefit in general healthy-weight women without metabolic history is less certain and not yet supported by prospective longevity data.

Perimenopause (Approximately Ages 45-55)

High benefit. This is arguably the single life stage where CGM data adds the most over standard labs. The metabolic shift can happen over 2-4 years before the final menstrual period, and a quarterly HbA1c simply does not have the resolution to catch progressive glucose dysregulation early.

Postmenopause

High benefit for women not on MHT and for women whose MHT was recently changed or discontinued. Moderate benefit for women on optimized transdermal MHT with no cardiovascular risk factors who have normal baseline metabolic labs.

Who Is Unlikely to Benefit Much

Young women with no metabolic risk factors, normal weight, regular cycles, and no family history will often see completely flat CGM traces. That data is reassuring but may not justify the cost of repeated sensor use unless specific concerns exist.

How to Get Actionable Data from Your CGM: Practical Interpretation Tips

Raw CGM data is easy to misread. A spike to 155 mg/dL is alarming in isolation and normal in context if it was caused by a high-glycemic-index meal followed by a 20-minute walk that returned glucose to 90 mg/dL within 90 minutes.

The Four Numbers to Review Every Two Weeks

1. Mean glucose (target: 79-100 mg/dL for longevity in non-diabetic women)
2. TIR at 70-140 mg/dL (target: above 90%)
3. CV (target: below 36%)
4. Time below 70 mg/dL (target: below 4%)

Patterns That Warrant a Clinical Conversation

• Fasting glucose consistently above 100 mg/dL across multiple days not explained by illness or significant stress
• Post-meal spikes above 140 mg/dL more than 4-5 times per week on a diet you consider reasonable
• CV above 36% with mean glucose in normal range (suggests reactive patterns worth investigating)
• Any reading below 54 mg/dL, even without symptoms

Menstrual Cycle Annotation

Most CGM apps do not integrate cycle tracking. Export your data manually or use a spreadsheet to label cycle days. Peer-reviewed work from researchers at Stanford confirmed that in a real-world study of 57 non-diabetic adults using CGM, individual responses to identical meals varied enormously, with factors including prior sleep, exercise, and hormonal status driving most of the variance. Cycle phase was not measured in that study, which itself illustrates the evidence gap: sex-disaggregated CGM longevity data in healthy women remains an area of active but incomplete research.

Making Sense of CGM Targets Across Guidelines

Different organizations set different thresholds, which creates confusion.

| Context | Band | Target TIR | |---|---|---| | ADA (T1D management) | 70-180 mg/dL | >70% | | ADA (T2D management) | 70-180 mg/dL | >70% | | ADA (Pregnancy, GDM/T1D) | 63-140 mg/dL | >70% | | Longevity medicine (non-diabetic) | 70-140 mg/dL | >90% | | Longevity medicine mean glucose | N/A | 79-100 mg/dL |

The longevity-medicine targets in the bottom two rows are not published in a single definitive guideline. They represent a working consensus drawn from observational epidemiology, the ARIC cohort data, and clinician practice at longevity-focused centers. Treat them as evidence-informed targets, not established clinical thresholds with the same authority as the ADA standards. The honest framing is: these are the numbers that preliminary data suggests are associated with lowest long-term metabolic and cardiovascular risk, but a randomized trial targeting CGM-derived longevity metrics in healthy non-diabetic women has not been published as of this writing.